| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 20 | 2023 | 320 | 2.690 |
Why?
|
| Myeloid-Derived Suppressor Cells | 4 | 2021 | 47 | 2.140 |
Why?
|
| Interleukin-12 | 12 | 2021 | 113 | 1.060 |
Why?
|
| Neoplasms | 8 | 2023 | 2755 | 1.030 |
Why?
|
| Interferon-gamma | 13 | 2017 | 499 | 0.970 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 533 | 0.810 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 286 | 0.690 |
Why?
|
| T-Lymphocytes | 5 | 2021 | 1690 | 0.640 |
Why?
|
| Lymphocyte Activation | 5 | 2017 | 684 | 0.590 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 29 | 0.560 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 532 | 0.530 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2023 | 819 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 8 | 2017 | 1008 | 0.440 |
Why?
|
| Antineoplastic Agents | 8 | 2011 | 1660 | 0.380 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2019 | 19 | 0.300 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 100 | 0.300 |
Why?
|
| Cytokines | 4 | 2005 | 1284 | 0.250 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 3291 | 0.230 |
Why?
|
| Chemokines | 3 | 2019 | 136 | 0.230 |
Why?
|
| Receptors, Fc | 3 | 2017 | 28 | 0.230 |
Why?
|
| Trastuzumab | 8 | 2017 | 131 | 0.220 |
Why?
|
| Neuroblastoma | 2 | 2019 | 513 | 0.210 |
Why?
|
| ErbB Receptors | 1 | 2004 | 284 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 7 | 2021 | 502 | 0.200 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 11 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 886 | 0.190 |
Why?
|
| Receptors, Interleukin-12 | 3 | 2008 | 9 | 0.190 |
Why?
|
| K562 Cells | 2 | 2019 | 95 | 0.190 |
Why?
|
| Receptors, IgG | 3 | 2008 | 54 | 0.190 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 2479 | 0.180 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 71 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 764 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 83 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2019 | 475 | 0.170 |
Why?
|
| Humans | 25 | 2023 | 123120 | 0.170 |
Why?
|
| Mice | 16 | 2021 | 17538 | 0.170 |
Why?
|
| Tumor Escape | 1 | 2020 | 61 | 0.170 |
Why?
|
| Animals | 17 | 2021 | 33793 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2020 | 98 | 0.160 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 263 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 151 | 0.160 |
Why?
|
| Adenoviridae | 1 | 2021 | 608 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2011 | 489 | 0.150 |
Why?
|
| Immunoglobulin G | 5 | 2015 | 769 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2017 | 44 | 0.140 |
Why?
|
| Ligands | 1 | 2019 | 533 | 0.140 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2017 | 96 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2020 | 660 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 7 | 2011 | 1002 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 676 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 290 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 287 | 0.120 |
Why?
|
| Receptors, Interleukin | 2 | 2005 | 32 | 0.110 |
Why?
|
| CD3 Complex | 3 | 2004 | 84 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 334 | 0.110 |
Why?
|
| DNA-Binding Proteins | 5 | 2005 | 2055 | 0.110 |
Why?
|
| Cancer Vaccines | 2 | 2004 | 186 | 0.100 |
Why?
|
| Trans-Activators | 4 | 2003 | 809 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 993 | 0.090 |
Why?
|
| Female | 15 | 2021 | 65527 | 0.090 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2011 | 23 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2006 | 1232 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 653 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 1080 | 0.090 |
Why?
|
| STAT4 Transcription Factor | 3 | 2008 | 7 | 0.080 |
Why?
|
| Transcriptome | 1 | 2015 | 903 | 0.080 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 2 | 2005 | 5 | 0.080 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 2 | 2005 | 6 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 2 | 2006 | 58 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 1681 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 246 | 0.080 |
Why?
|
| CD56 Antigen | 2 | 2004 | 26 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2008 | 617 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 96 | 0.070 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 60 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2006 | 665 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2004 | 803 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 376 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 6 | 2005 | 4354 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2005 | 1610 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 1061 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 324 | 0.070 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2005 | 20 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2004 | 757 | 0.060 |
Why?
|
| Interleukins | 1 | 2006 | 118 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 135 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 2005 | 221 | 0.060 |
Why?
|
| Monokines | 1 | 2004 | 2 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 144 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2004 | 13 | 0.060 |
Why?
|
| CpG Islands | 1 | 2005 | 320 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2004 | 171 | 0.050 |
Why?
|
| Transfection | 1 | 2005 | 1068 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 469 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 4 | 2005 | 69 | 0.050 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2003 | 32 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2004 | 216 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 1386 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 810 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 207 | 0.050 |
Why?
|
| Time Factors | 4 | 2005 | 6221 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1290 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2002 | 91 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 807 | 0.050 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 43 | 0.050 |
Why?
|
| Shock | 1 | 2002 | 90 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2021 | 233 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2002 | 190 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 230 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2005 | 3722 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 110 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2307 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2003 | 747 | 0.040 |
Why?
|
| Genotype | 1 | 2004 | 2533 | 0.040 |
Why?
|
| Macrophages | 1 | 2002 | 605 | 0.040 |
Why?
|
| Sepsis | 1 | 2002 | 476 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 58 | 0.040 |
Why?
|
| Feeder Cells | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2016 | 45 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 2016 | 32 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4284 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2006 | 369 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 345 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2004 | 4700 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 385 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2005 | 12119 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2005 | 3040 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2017 | 4494 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 2004 | 224 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 351 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2003 | 2394 | 0.030 |
Why?
|
| Aged | 3 | 2005 | 19101 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1012 | 0.020 |
Why?
|
| Spleen | 2 | 2003 | 272 | 0.020 |
Why?
|
| Mice, SCID | 2 | 2003 | 570 | 0.020 |
Why?
|
| Middle Aged | 3 | 2005 | 26002 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 426 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1872 | 0.020 |
Why?
|
| Adult | 3 | 2005 | 29010 | 0.020 |
Why?
|
| Male | 3 | 2021 | 60140 | 0.020 |
Why?
|
| Cell Line | 2 | 2004 | 2771 | 0.020 |
Why?
|
| Syk Kinase | 1 | 2008 | 12 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 861 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 1474 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 91 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 130 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 211 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 369 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2006 | 61 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 57 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 340 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2006 | 55 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2005 | 18 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 195 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 2524 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 2004 | 12 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2004 | 64 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 488 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 525 | 0.020 |
Why?
|
| L-Selectin | 1 | 2004 | 21 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2004 | 29 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 105 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 555 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2005 | 237 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 382 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 524 | 0.010 |
Why?
|
| Measles virus | 1 | 2003 | 10 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 37 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 2003 | 39 | 0.010 |
Why?
|
| Chromium | 1 | 2002 | 6 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 393 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 147 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 194 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 312 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2003 | 239 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 73 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2003 | 192 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 71 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 260 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 697 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 831 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 117 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 133 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 709 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 63 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 143 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 2002 | 46 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 780 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 357 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 720 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2002 | 300 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 341 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 422 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2002 | 457 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1688 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 514 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 2695 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 3867 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 2000 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2002 | 771 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1782 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 6374 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 1593 | 0.010 |
Why?
|